Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Sued Over Tuschl-II IP by University of Utah


Just days after announcing that it had settled a dispute over ownership of key intellectual property, Alnylam Pharmaceuticals disclosed that it has been sued by the University of Utah over the same IP.

According to an Alnylam filing with the US Securities and Exchange Commission, the university has alleged that one of its researchers, Brenda Bass, is the inventor of the technology covered in the so-called Tuschl-II patent estate.

Alnylam said it disagrees with the claims and intends to “defend the action vigorously.”

The Tuschl-II patent applications relate to the use of siRNAs, 21 to 23 nucleotides in length and with 2- to 3-nucleotide-long 3' overhangs, to target specific mRNA degradation in mammals. A related patent estate, called Tuschl-I, claims essentially the same siRNA constructs, but without the overhangs.

In 2009, Alnylam and Max Planck, which hold the exclusive rights to Tuschl-II, sued the Whitehead Institute for Biomedical Research, the Massachusetts Institute of Technology, and the University of Massachusetts for allegedly including data from the patent portfolio in Tuschl-I patent applications (GSN 7/9/2009).

The dispute was settled earlier this month (GSN 3/17/2011).

But with the latest litigation, Alnylam and Max Planck's rights to the technology appear to be in question once more.

Adding to Alnylam's woes is a separate lawsuit filed by partner Tekmira Pharmaceuticals, which alleges that Alnylam stole trade secrets related to proprietary lipid delivery technology (GSN 3/17/2011).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.